Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer
NCT01270698
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
26
Enrollment
INDUSTRY
Sponsor class
Conditions
Metastatic Colorectal Cancer
Interventions
DRUG:
IMMU-130
Sponsor
Gilead Sciences